Effect of genistein administration on the recovery of spermatogenesis in the busulfan-treated rat testis

Chi, Heejun; Chun, Kangwoo; Son, Hyukjun; Kim, Jonghyun; Kim, Giyoung; Roh, Sungil

추천

검색

자료유형: 학술저널

저자정보: Chi, Heejun (i-Dream Research Center, MizMedi Hospital) Chun, Kangwoo (i-Dream Research Center, MizMedi Hospital) Son, Hyukjun (i-Dream Research Center, MizMedi Hospital) Kim, Jonghyun (i-Dream Research Center, MizMedi Hospital) Kim, Giyoung (i-Dream Research Center, MizMedi Hospital) Roh, Sungil (i-Dream Research Center, MizMedi Hospital)

저널정보: 대한생식의학회 Clinical and experimental reproductive medicine : CERM Clinical and experimental reproductive medicine : CERM 제40권 제2호

발행연도: 2013.1

수록면: 60 - 66 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: Impairment of spermatogenesis has been identified as an inevitable side effect of cancer treatment. Although estrogen treatment stimulates spermatogenic recovery from the impaired spermatogenesis by suppressing the intra-testicular testosterone (ITT) level, side effects of estrogen are still major impediments to its clinical application in humans. Soybeans are rich in genistein, which is a phytoestrogen that binds to estrogen receptors and has an estrogenic effect. We investigated the effects of genistein administration on ITT levels, testis weight, and recovery of spermatogenesis in rats treated with a chemotherapeutic agent, busulfan. Methods: Busulfan was administered intraperitoneally to rats, and then a GnRH agonist was injected subcutaneously into the back, or genistein was administered orally. Results: The weight of the testes was significantly reduced by the treatment with busulfan. The testis weight was partially restored after busulfan treatment by additional treatment with either the GnRH agonist or genistein. Busulfan also induced atrophy of a high percentage of the seminiferous tubules, but this percentage was decreased by additional treatment with either the GnRH agonist or genistein. Treatment with genistein was effective at suppressing and maintaining ITT levels comparable to that in the GnRH agonist group. Conclusion: Genistein effectively suppressed ITT levels and stimulated the recovery of spermatogenesis in rats treated with a chemotherapeutic drug. This suggests that genistein may be a substitute for estrogens, for helping humans to recover fertility after cancer therapy without the risk of side effects.

#Drug therapy #Busulfan #Genistein #Recovery of spermatogenesis

참고문헌 (41)

참고문헌 신청

Kangasniemi M / 1995 / Protection against procarbazine-induced testicular damage by GnRHagonist and antiandrogen treatment in the rat / Endocrinology 136:3677~3680

Meistrich ML / 1997 / Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia / J Androl 18:80~87

Meistrich ML / 1999 / Restoration of spermatogenesis by hormone treatment after cytotoxic therapy / Acta Paediatr Scand 88:19~22

Kangasniemi M / 1995 / Rapid protection of rat spermatogenic stem cells against procarbazine by treatment with a gonadotropin-releasing hormone antagonist (Nal-Glu) and an antiandrogen (flutamide) / Endocrinology 136:2881~2888

Shetty G / 2000 / Gonadotropin-releasing hormone analogs stimulate and testosterone inhibits the recovery of spermatogenesis in irradiated rats / Endocrinology 141:1735~1745